Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. Show more
Location: 3891 Ranchero Drive, Ann Arbor, MI, 48108, United States | Website: https://www.esperion.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
235.9M
52 Wk Range
$0.69 - $3.94
Previous Close
$1.24
Open
$1.23
Volume
2,095,338
Day Range
$1.17 - $1.24
Enterprise Value
674.5M
Cash
114.6M
Avg Qtr Burn
-25.03M
Insider Ownership
0.58%
Institutional Own.
59.27%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Nexlizet (bempedoic acid and ezetimibe) Details Hypercholesterolemia, Atherosclerotic cardiovascular disease , Heterozygous familial hypercholesterolemia, Cardiovascular risk reduction | Approved Quarterly sales | |
Nexletol (bempedoic acid) Details Heterozygous familial hypercholesterolemia, Atherosclerotic cardiovascular disease , Hypercholesterolemia | Approved Quarterly sales | |
Bempedoic acid Details Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia | Phase 3 Initiation |